Insulet Meets on the Top Line, Misses Where It Counts
Insulet (NAS: PODD) reported earnings on Feb. 9. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Insulet met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP loss per share dropped.
Gross margins dropped, operating margins increased, and net margins improved.
Insulet notched revenue of $47.2 million. The 17 analysts polled by S&P Capital IQ expected revenue of $47.4 million. GAAP sales were 70% higher than the prior-year quarter's $27.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.30. The 14 earnings estimates compiled by S&P Capital IQ predicted -$0.26 per share. GAAP EPS were -$0.30 for Q4 against -$0.50 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 42.5%, 730 basis points worse than the prior-year quarter. Operating margin was -22.3%, 40 basis points better than the prior-year quarter. Net margin was -30.4%, 4,470 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $47.9 million. On the bottom line, the average EPS estimate is -$0.23.
Next year's average estimate for revenue is $217.9 million. The average EPS estimate is -$0.61.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 69 members out of 109 rating the stock outperform, and 40 members rating it underperform. Among 39 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 27 give Insulet a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $23.15.
Over the decades, small-cap stocks like Insulet have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Insulet to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.